{"numRecords":"81","DataElementQueryResults":[{"publicId":"4156053","version":"1","preferredName":"Person Intake Type","preferredDefinition":"A human being._The process of taking in a substance, especially by eating or drinking, or the quantities thereof; admittance of people to a place or organization at a particular time._Something distinguishable as an identifiable class based on common qualities.","longName":"4155935v1.0:4156012v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F250136F-E9B1-44FD-E040-BB89AD436D96","latestVersionIndicator":"Yes","beginDate":"2014-02-13","endDate":null,"createdBy":"KARNATAA","dateCreated":"2014-02-13","modifiedBy":"CHILLIJ","dateModified":"2015-06-22","changeNote":"6/22/15 released per Anu; used on active study. jc  02/13/2014. Created for CITN study. AK","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4156079","version":"1","preferredName":"Person Intake Fluid Sample Volume Number","preferredDefinition":"A human being._The process of taking in a substance, especially by eating or drinking, or the quantities thereof; admittance of people to a place or organization at a particular time._Numeric value to represent the volume of a fluid sample, expressed as a number of milliliters (ml).","longName":"4155935v1.0:2222684v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F250136F-EA35-44FD-E040-BB89AD436D96","latestVersionIndicator":"Yes","beginDate":"2014-02-13","endDate":null,"createdBy":"KARNATAA","dateCreated":"2014-02-13","modifiedBy":"CHILLIJ","dateModified":"2015-06-22","changeNote":"6/22/15 released per Anu; used on active study. jc 02/13/2014. Created for CITN study. AK","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4551839","version":"1","preferredName":"HTLV-1 Positive Finding Diagnosis Yes No Indicator","preferredDefinition":"Text term to signify a positive Human T-lymphotropic virus-1 (HTLV-1) finding in an individual.","longName":"HTLV1_POS_DX_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"062E45D7-A2F3-1940-E050-BB89AD436B5F","latestVersionIndicator":"Yes","beginDate":"2014-10-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-24","modifiedBy":"KNABLEJ","dateModified":"2016-04-15","changeNote":"4/15/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4551874","version":"1","preferredName":"Attenuated Live Virus Vaccine Immunization 30 Day Prior First Therapy Yes No Indicator","preferredDefinition":"Text term to signify whether a patient has been vaccinated with a live vaccine within 30 days of receiving the first dose of clinical trial treatment.","longName":"VACC_30D_TX_YN_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"062F25F7-340F-0264-E050-BB89AD430A2A","latestVersionIndicator":"Yes","beginDate":"2014-10-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-24","modifiedBy":"BERGANTW","dateModified":"2019-08-19","changeNote":"4/15/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4551901","version":"1","preferredName":"Gravida Breast Feeding Fertile Patient Until 120 Day Post Treatment Regimen Yes No Not Applicable Indicator","preferredDefinition":"Text term to signify whether a woman is pregnant or nursing an infant or expecting to conceive duration the time of a clinical trial throughout 120 days after the final dose of trial treatment.","longName":"4551900v1.0:3506036v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"062E8EF7-EA95-682F-E050-BB89AD4352AE","latestVersionIndicator":"Yes","beginDate":"2014-10-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-24","modifiedBy":"KNABLEJ","dateModified":"2017-10-09","changeNote":"4/15/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4551975","version":"1","preferredName":"Stage III Stage IV Relapsed Refractory Progressive Disease Mycosis Fungoides Sezary Syndrome Post One Systemic Treatment Regimen Yes No Indicator","preferredDefinition":"Text term to signify a patient with Stage III or IV refractory, relapsed or progressive Sezary Syndrome or Mycosis Fungoides after one standard systemic therapy regimen.","longName":"SS_MF_PRG_DZ_YN_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06303AFE-7AFA-F88F-E050-BB89AD431491","latestVersionIndicator":"Yes","beginDate":"2014-10-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-24","modifiedBy":"CHILLIJ","dateModified":"2015-05-28","changeNote":"5/28/15 released for use on CITN-10 Eligibility Checklist form. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4552571","version":"1","preferredName":"Washout Period Progressive Disease Relapse To Enrollment Adverse Event Recovery Greater Than or Equal 4 Week Cytotoxic Chemotherapy 8 Week Alemtuzumab Occurrence Yes No Not Applicable Indicator","preferredDefinition":"Text term to signify whether at least four weeks have passed since a patient received cytotoxic systemic chemotherapy, or at least eight weeks have passed since alemutuzumab was received by a patient between the documentation of relapse/progressive disease and enrollment into a clinical trial.","longName":"WSH_4WK_8WK_AGT_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0667E923-E999-933F-E050-BB89AD436428","latestVersionIndicator":"Yes","beginDate":"2014-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-27","modifiedBy":"VUJANOVA","dateModified":"2018-10-10","changeNote":"4/15/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4552611","version":"1","preferredName":"Washout Period Progressive Disease Relapse To Enrollment Adverse Event Recovery Greater Than or Equal 15 Week Urelumab Ipilimumab Targeting Agent Yes No Not Applicable Indicator","preferredDefinition":"Text term to signify whether at least 15 weeks have lapsed since a patient received a dose of anti-CD137, Ipilimumab, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, between the time of documentation of relapse/progressive disease and enrollment into a clinical trial.","longName":"WH_15WK_ANTCD137_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0668D49C-3124-9EDD-E050-BB89AD430DDA","latestVersionIndicator":"Yes","beginDate":"2014-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-27","modifiedBy":"SARAHB","dateModified":"2018-06-25","changeNote":"4/15/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4552636","version":"1","preferredName":"Washout Period Progressive Disease Relapse To Enrollment Adverse Event Recovery Greater Than or Equal 2 Week Therapeutic Procedure Agent Administration Occurrence Yes No Not Applicable Indicator","preferredDefinition":"Text term to signify whether a person who received therapeutic agents or procedures has recovered from all adverse events for at least two weeks between the period of documentation of relapse/progression and enrollment into a clinical trial.","longName":"PT_RECV_TX_YNNA_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0668F78D-850E-7AEF-E050-BB89AD436F03","latestVersionIndicator":"Yes","beginDate":"2014-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-27","modifiedBy":"SARAHB","dateModified":"2018-06-25","changeNote":"4/15/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4552645","version":"1","preferredName":"Washout Period Progressive Disease Relapse To Enrollment Adverse Event Recovery Greater Than or Equal 2 Week Retinoid Interferon Therapeutic Corticosteroid Occurrence Yes No Not Applicable Indicator","preferredDefinition":"Text term to signify whether a person who may have received retinoids, interferons, vorinostat, romidepsin, denileukin, diftitox, and therapeutic doses of oral corticosteroids has recovered from all adverse events for at least two weeks between the period of documentation of relapse/progression and enrollment into a clinical trial.","longName":"WH_AE_2WK_YNNA_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0668F78D-8570-7AEF-E050-BB89AD436F03","latestVersionIndicator":"Yes","beginDate":"2014-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-27","modifiedBy":"KNABLEJ","dateModified":"2017-10-05","changeNote":"4/15/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4552649","version":"1","preferredName":"Washout Period Progressive Disease Relapse To Enrollment Adverse Event Recovery Greater Than or Equal 2 Week Phototherapy Occurrence Yes No Not Applicable Indicator","preferredDefinition":"Text term to signify whether at least two weeks have lapsed since a patient received any phototherapy between the time of documentation of relapse/progression and enrollment into a clinical trial.","longName":"WH_2WK_PHTX_YNNA_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0668F78D-85C1-7AEF-E050-BB89AD436F03","latestVersionIndicator":"Yes","beginDate":"2014-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-27","modifiedBy":"VUJANOVA","dateModified":"2018-10-10","changeNote":"4/15/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4552654","version":"1","preferredName":"Patient Greater Than or Equal One Week Topical Retinoid Mechlorethamine Imiquimod Clinical Trial Eligibility Criteria Yes No Not Applicable Indicator","preferredDefinition":"Text term to signify whether a patient has received topic therapy that includes retinoids, nitrogen mustard or Imiquimod with the past one week.","longName":"PT_1WK_MECH_YNNA_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0668F78D-85EF-7AEF-E050-BB89AD436F03","latestVersionIndicator":"Yes","beginDate":"2014-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-27","modifiedBy":"KNABLEJ","dateModified":"2017-10-09","changeNote":"4/15/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4572062","version":"1","preferredName":"Measured Calculated Creatinine Greater Than Equal 1.5 Times Upper Limit Normal Patient Creatinine Clearance Greater Than Equal 60 Millimeter Minute Occurrence Yes No Indicator","preferredDefinition":"Text term to signify whether a patient with a (serum) Creatinine level of greater than or equal 1.5 times the institution upper limit of normal (ULN) has a measured/calculated Creatinine clearance of greater than or equal to 60 millimeters per minute (mL/min).","longName":"CRCL_60_CREAT_YN_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"070C0E9D-A895-6F4F-E050-BB89AD43146A","latestVersionIndicator":"Yes","beginDate":"2014-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-04","modifiedBy":"SBREXT","dateModified":"2016-09-15","changeNote":"4/15/16 Released, used in CITN-10 and CITN-09. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4572216","version":"1","preferredName":"Measured Calculated Total Bilirubin Measurement Greater Than 1.5 Upper Limit of Normal Patient Direct Bilirubin Measurement Greater Than Equal Upper Limit of Normal Occurrence Yes No Indicator","preferredDefinition":"Text term to signify whether a patient with total bilirubin level of greater than 1.5 times the institution upper limit of normal (ULN) has a direct bilirubin measurement of greater than or equal the institution upper limit of normal.","longName":"TBIL_DBIL_YNNA_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"070C606C-F773-0BDD-E050-BB89AD437A7D","latestVersionIndicator":"Yes","beginDate":"2014-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-04","modifiedBy":"BOWSERC","dateModified":"2021-12-09","changeNote":"4/15/16 Released, used in CITN-10 and CITN-09. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4572226","version":"1","preferredName":"Measured Patient SGOT Less Than Equal 2.5 Upper Limit Normal Occurrence Yes No Indicator","preferredDefinition":"Text term to signify whether a patient has a measured SGOT (AST) serum level that is less than or equal to 2.5 times the institution upper limit of normal (ULN).","longName":"PT_SGOT_2.5ULN_YNIND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"070C606C-F85B-0BDD-E050-BB89AD437A7D","latestVersionIndicator":"Yes","beginDate":"2014-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-04","modifiedBy":"KNABLEJ","dateModified":"2016-04-15","changeNote":"4/15/16 Released, used in CITN-10 and CITN-09. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4572484","version":"1","preferredName":"Measured Patient SGOT (AST) Less Than Equal 5 Times Upper Limit Normal With Hepatic Metastasis Occurrence Yes No Indicator","preferredDefinition":"Text term to signify that a patient with liver metastases has a serum SGOT value of less than or equal to 5 times the institution upper limit of normal (ULN).","longName":"SGOT_5XULN_HEP_YNIND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0711D30F-F9D7-329E-E050-BB89AD430544","latestVersionIndicator":"Yes","beginDate":"2014-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-04","modifiedBy":"KNABLEJ","dateModified":"2016-04-15","changeNote":"4/15/16 Released, used in CITN-10 and CITN-09. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4572514","version":"1","preferredName":"Measured Patient SGPT (ALT) Less Than Equal 2.5 Times Upper Limit Normal Occurrence Yes No Indicator","preferredDefinition":"Text term to signify whether a patient has a serum SGPT (ALT) that is less than or equal to 2.5 times institution upper limit of normal (ULN).","longName":"PT_SGPT_2.5ULN_YNIND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"07126CBD-A7C1-F4F8-E050-BB89AD43470B","latestVersionIndicator":"Yes","beginDate":"2014-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-04","modifiedBy":"KNABLEJ","dateModified":"2016-04-15","changeNote":"4/15/16 Released, used in CITN-10 and CITN-09. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4572654","version":"1","preferredName":"Measured Patient SGPT (ALT) Less Than Equal 5 Times Upper Limit Normal With Hepatic Metastasis Occurrence Yes No Indicator","preferredDefinition":"Text term to signify that a patient with liver metastases has a serum SGPT (ALT) value of less than or equal to 5 times the institution upper limit of normal (ULN).","longName":"SGPT_5XULN_HEP_YNIND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"071CBC41-D9EF-EA4C-E050-BB89AD432562","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-05","modifiedBy":"KNABLEJ","dateModified":"2016-04-15","changeNote":"4/15/16 Released, used in CITN-10 and CITN-09. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4572675","version":"1","preferredName":"Measured Less Than or Equal 1.5 Times Upper Limit Normal International Normalized Ratio Within Anticoagulant Agent Therapeutic Range Occurrence Yes No Indicator","preferredDefinition":"Text term to signify whether the result of the International Normalized Ratio (INR) is less than or equal to 1.5 times the institution upper limit of normal (ULN), unless the use of anticoagulant therapy requires a therapeutic range that must be observed.","longName":"INR_1.5ULN_COA_YNIND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"071CBC41-DA4A-EA4C-E050-BB89AD432562","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-05","modifiedBy":"KNABLEJ","dateModified":"2016-04-15","changeNote":"4/15/16 Released, used in CITN-10 and CITN-09. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4572679","version":"1","preferredName":"Measured Less Than or Equal 1.5 Times Upper Limit of Normal Prothrombin Time Within Anticoagulant Agent Therapeutic Range Occurrence Yes No Indicator","preferredDefinition":"Text term to signify whether the result of the Prothrombin Time (PT) is less than or equal to 1.5 times the institution upper limit of normal (ULN), unless the use of anticoagulant therapy requires a therapeutic range that must be observed.","longName":"PT_1.5ULN_COAG_YNIND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"071CBC41-DA8E-EA4C-E050-BB89AD432562","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-05","modifiedBy":"KNABLEJ","dateModified":"2016-04-15","changeNote":"4/15/16 Released, used in CITN-10 and CITN-09. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4572694","version":"1","preferredName":"Measured Less Than or Equal 1.5 Times Upper Limit of Normal Activated Partial Thromboplastin Time (aPTT) Within Anticoagulant Agent Therapeutic Range Occurrence Yes No Indicator","preferredDefinition":"Text term to signify whether the result of the Activated Partial Thromboplastin Time (aPTT) is less than or equal to 1.5 times the institution upper limit of normal (ULN), unless the use of anticoagulant therapy requires a therapeutic range that must be observed.","longName":"PPT_1.5ULN_COA_YNIND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"071CBC41-DAD2-EA4C-E050-BB89AD432562","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-05","modifiedBy":"REEVESD","dateModified":"2015-04-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4572699","version":"1","preferredName":"Measurable Modified Severity Weighted Assessment Tool (mSWAT) Disease Present Yes No Indicator","preferredDefinition":"Text term to signify whether disease measured using the Modified Severity-Weighted Assessment Tool (mSWAT) is present.","longName":"MSWAT_DZ_PRES_YNIND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"071CBC41-DB18-EA4C-E050-BB89AD432562","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-05","modifiedBy":"KNABLEJ","dateModified":"2017-10-09","changeNote":"4/15/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4573647","version":"1","preferredName":"Anti-PD-1 Anti-PD-L-1 Anti-PD-L2 Prior Therapy Administration Yes No Indicator","preferredDefinition":"Text term to signify whether an individual has received prior therapy with anti-PD-1, anti-PD-L-1 and anti-PD-L2.","longName":"ANTIPD1_L1_L2_YNIND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"071CBC41-DB5D-EA4C-E050-BB89AD432562","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-05","modifiedBy":"KUMMEROA","dateModified":"2022-07-20","changeNote":"4/15/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4573655","version":"1","preferredName":"Failure Resolve Recover Patient Chemotherapy Targeted Molecular Therapy Past 4 Week Occurrence Yes No Indicator","preferredDefinition":"Text term to signify that a patient has received chemotherapy or targeted small molecule therapy with the past 4 weeks prior to study entry, or has not recovered from adverse events associated with agent(s) administered more than 4 weeks earlier.","longName":"FL_REC_TX_4WK_YNIND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"071CBC41-DBB9-EA4C-E050-BB89AD432562","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-05","modifiedBy":"LEEW","dateModified":"2018-07-25","changeNote":"4/15/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4573660","version":"1","preferredName":"Investigational Medical Device Investigational New Drug Participation Within 4 Week First Dose Treatment Regimen Occurrence Yes No Indicator","preferredDefinition":"Text term to signify whether a patient is currently participating in or has participated in an investigational new drug or investigational medical device study within 4 weeks of the first dose of a treatment regimen.","longName":"DEV_IND_PT_4WK_YNIND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"071E04E1-F25E-C83E-E050-BB89AD435EC1","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-05","modifiedBy":"SERIANNJ","dateModified":"2021-04-26","changeNote":"4/15/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4574645","version":"1","preferredName":"Therapeutic Corticosteroid Or Immunodeficiency Diagnosis 7 Day Prior Treatment Regimen First Dose Occurrence Yes No Indicator","preferredDefinition":"Text term to signify that a patient has a diagnosis of immunodeficiency or was receiving therapeutic systemic steroids or any other form of immunosuppressive therapy within 7 days before the first dose of trial treatment.","longName":"IMMUN_7D_PR_TX_YNIND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0722DA73-8454-32CB-E050-BB89AD434045","latestVersionIndicator":"Yes","beginDate":"2014-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-05","modifiedBy":"KNABLEJ","dateModified":"2018-09-13","changeNote":"4/15/16 Released, used in CITN-10 and CITN-09. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4575195","version":"1","preferredName":"Severe Autoimmune History Or Active Disease Diagnosis With Past 3 Month Therapy Clinical Trial Eligibility Yes No Indicator","preferredDefinition":"Text term to signify whether a patient has an active autoimmune disease needing treatment in the past 3 months or a history of severe autoimmune disease, or a syndrome that requires autoimmunosuppressive agents.","longName":"AUTOIM_3MO_TX_YNIND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"073158A8-03A6-8BD3-E050-BB89AD434D34","latestVersionIndicator":"Yes","beginDate":"2014-11-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-06","modifiedBy":"SBR","dateModified":"2018-10-26","changeNote":"5/12/15 Released as requested by Citn curator for use on a form and addition of alternate question text. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4718126","version":"1","preferredName":"Person Human Immunodeficiency Virus Physician Clinical Study Approval Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"The yes/no indicator that represents whether the physician providing the patient's care for HIV approves entering the study as part of the patient's eligibility to participate in the clinical trial.","longName":"PRSN_HIV_PHY_APPRVL_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EEC8650-A55D-7DED-E050-BB89AD43437C","latestVersionIndicator":"Yes","beginDate":"2015-02-12","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-02-12","modifiedBy":"FORMBUILDER","dateModified":"2015-03-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4841991","version":"1","preferredName":"Stage I Stage II Stage III Stage IV Refractory Progressive Disease Recurrent Disease Mycosis Fungoides Sezary Syndrome Post Greater Than or Equal To One Systemic Treatment Regimen Progressive Disease Yes No Indicator","preferredDefinition":"A yes/no response to indicate if a patient with Stage I, II, III or IV refractory, relapsed or progressive Sezary Syndrome or Mycosis Fungoides after at least one standard systemic therapy regimen.","longName":"S1_4_MF_PRG_DZ_YN_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"172A775D-3A43-EAFD-E050-BB89AD4308B8","latestVersionIndicator":"Yes","beginDate":"2015-05-28","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2015-05-28","modifiedBy":"KNABLEJ","dateModified":"2017-10-05","changeNote":"5/28/15 created for CITN study.  jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4842032","version":"1","preferredName":"Administration Eligibility Determination Indicator","preferredDefinition":"The act of administration of any UGT1A9 inhibitor.","longName":"ADM_ELIG_DETR_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"172A775D-3AAE-EAFD-E050-BB89AD4308B8","latestVersionIndicator":"Yes","beginDate":"2015-05-28","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2015-05-28","modifiedBy":"CHILLIJ","dateModified":"2015-05-28","changeNote":"5/28/15 created for CITN study. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4842054","version":"1","preferredName":"Prior Skin-Directed Therapy Administered Indicator","preferredDefinition":"A yes/no response to indicate if a patient has been given skin-directed therapy prior to a study.","longName":"PRIO_SKINTX_ADM_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"172A775D-3B03-EAFD-E050-BB89AD4308B8","latestVersionIndicator":"Yes","beginDate":"2015-05-28","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2015-05-28","modifiedBy":"FORMBUILDER","dateModified":"2015-05-29","changeNote":"5/28/15 created for CITN study based on CDE 2195087 with new, CITN approved, EVS CUI C121969.  jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4925171","version":"2","preferredName":"Patient Curative Surgery Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"A yes/no response for questions to determine if a person meets the eligibility criteria for curative surgery.","longName":"4925153v1.1:3506068v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7520033E-D170-2151-E053-F662850A12D0","latestVersionIndicator":"Yes","beginDate":"2018-09-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-09-05","modifiedBy":"SOKKERL","dateModified":"2018-09-05","changeNote":"9/5/18 Version DEC and CDE to correct definiton source. LS 8/5/15 released/tt_7/29/15 curated for CITN elig/tt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4925911","version":"1","preferredName":"Allogenic Bone Marrow Transplantation Prior Performed Yes No Indicator","preferredDefinition":"A yes/no response as to whether a previous allogenic bone marrow transplant was perfomed.","longName":"4925698v1.0:3506068v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1C2D13B2-54E4-7192-E050-BB89AD4375B4","latestVersionIndicator":"Yes","beginDate":"2015-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-07-31","modifiedBy":"FORMBUILDER","dateModified":"2015-09-17","changeNote":"8/5/2015 released/tt_7/31/15 curated for CITN/tt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4926176","version":"1","preferredName":"Concurrent Anticoagulant Agent Therapeutic Procedure Yes No Indicator","preferredDefinition":"A yes/no response for questions addressing concurrent treatment with anticoagulant agents.","longName":"4926133v1.0:3506068v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1C305A90-BA74-9EA3-E050-BB89AD430163","latestVersionIndicator":"Yes","beginDate":"2015-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-07-31","modifiedBy":"FORMBUILDER","dateModified":"2015-09-17","changeNote":"8/5/2015 released/tt_7/31/2015 curated for CITN/tt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4926251","version":"1","preferredName":"Regional Lymph Node Resection Status","preferredDefinition":"A negative/positive response for questions addressing the status of resected regional lymph nodes.","longName":"4926212v1.0:4926232v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1C305A90-BB2A-9EA3-E050-BB89AD430163","latestVersionIndicator":"Yes","beginDate":"2015-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-07-31","modifiedBy":"TAYLORT","dateModified":"2015-10-06","changeNote":"10/6/15 released/tt_7/31/2015 curatd for CITN/tt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5027551","version":"1","preferredName":"Folliculotropic Mycosis Fungoides Occurrence Yes No Indicator","preferredDefinition":"A yes/no response to indicate occurrence of Folliculotropic Mycosis Fungoides.","longName":"5027534v1.0:3506068v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"210E2560-613F-5557-E050-BB89AD434FB9","latestVersionIndicator":"Yes","beginDate":"2015-10-01","endDate":null,"createdBy":"KARNATAA","dateCreated":"2015-10-01","modifiedBy":"KNABLEJ","dateModified":"2020-12-11","changeNote":"12/11/20 jk Released per 4Q20 qtrly review; used on form, added CITN origin.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5027556","version":"1","preferredName":"Large T-Cell Transformation Occurrence Yes No Indicator","preferredDefinition":"A yes/no response to indicate occurrence of large T-cell transformation.","longName":"5027555v1.0:3506068v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"210E2560-6181-5557-E050-BB89AD434FB9","latestVersionIndicator":"Yes","beginDate":"2015-10-01","endDate":null,"createdBy":"KARNATAA","dateCreated":"2015-10-01","modifiedBy":"KNABLEJ","dateModified":"2020-12-11","changeNote":"12/11/20 jk Released per 4Q20 qtrly review; used on form, added CITN origin.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5027592","version":"1","preferredName":"Large T-Cell Transformation Occurrence Body System Anatomic Site Names","preferredDefinition":"The anatomic location of the large T- cell transformation occurrence.","longName":"5027555v1.0:2185911v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"210E2560-62DF-5557-E050-BB89AD434FB9","latestVersionIndicator":"Yes","beginDate":"2015-10-01","endDate":null,"createdBy":"KARNATAA","dateCreated":"2015-10-01","modifiedBy":"KNABLEJ","dateModified":"2020-12-11","changeNote":"12/11/20 jk Released per 4Q20 qtrly review; used on form, added CITN origin.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5028016","version":"1","preferredName":"Sezary Circulating Tumor Cell Indicator","preferredDefinition":"A yes/no response to indicate presence of circulatory Sezary cells.","longName":"SEZARY_CTC_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"21738239-4C63-B727-E050-BB89AD43168E","latestVersionIndicator":"Yes","beginDate":"2015-10-06","endDate":null,"createdBy":"KARNATAA","dateCreated":"2015-10-06","modifiedBy":"COOPERM","dateModified":"2019-06-10","changeNote":"12/13/17 jk Chg SN to text, saved system-generated as alt name; added alt question; released CDE.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5028033","version":"1","preferredName":"Sezary Cell Circulating Tumor Cell Count Absolute Number","preferredDefinition":"The absolute number of circulating Sezary cells.","longName":"5028015v1.0:5028032v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"217476E3-5A4A-F7E7-E050-BB89AD436C27","latestVersionIndicator":"Yes","beginDate":"2015-10-06","endDate":null,"createdBy":"KARNATAA","dateCreated":"2015-10-06","modifiedBy":"HARTLEYG","dateModified":"2020-02-10","changeNote":"Released as part of the quarterly metrics clean-up_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5028974","version":"1","preferredName":"Sezary Cell Percent Total Lymphocyte Count Value","preferredDefinition":"Percent Sezary cells of total lymphocytes.","longName":"5028914v1.0:2019325v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"21AF4A18-BEF9-4FBF-E050-BB89AD430E10","latestVersionIndicator":"Yes","beginDate":"2015-10-09","endDate":null,"createdBy":"KARNATAA","dateCreated":"2015-10-09","modifiedBy":"COOPERM","dateModified":"2019-06-10","changeNote":"Created for CITN-10 study. 10/9/2015 AK.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5046312","version":"1","preferredName":"Modified Severity Weighted Assessment Tool (mSWAT) Score","preferredDefinition":"A range of numeric values that represent the modified severity weighted assessment tool (mSWAT) score.","longName":"mSWAT_SCR","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"24C10688-36AC-2B87-E050-BB89AD431821","latestVersionIndicator":"Yes","beginDate":"2015-11-17","endDate":null,"createdBy":"KARNATAA","dateCreated":"2015-11-17","modifiedBy":"COOPERM","dateModified":"2019-04-29","changeNote":"4/19/19 jk released for reuse by CCR.  12/1/15 jk created for CITN-10 protocol.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5053232","version":"1","preferredName":"Modified Severity Weighted Assessment Tool (mSWAT) Percent Change From Baseline Value","preferredDefinition":"A computed percent of change from the starting point to the current assessment using the modified severity weighted assessment tool (mSWAT).","longName":"5052933v1.0:3382692v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"253A6C63-0C0F-27AF-E050-BB89AD437159","latestVersionIndicator":"Yes","beginDate":"2015-11-23","endDate":null,"createdBy":"KARNATAA","dateCreated":"2015-11-23","modifiedBy":"KNABLEJ","dateModified":"2020-12-11","changeNote":"12/11/20 jk Released per 4Q20 qtrly review; used on form, added CITN origin, only CITN use.  12/1/2015 AK Created for CITN-10 protocol.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5065451","version":"1","preferredName":"Modified Severity Weighted Assessment Tool (mSWAT) Indicator","preferredDefinition":"A yes/no/unknown/not applicable response to indicate if a clinical assessment is made using the modified severity weighted assessment tool (mSWAT).","longName":"5046292v1.0:3506035v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"25DE6D97-2DBE-E431-E050-BB89AD430827","latestVersionIndicator":"Yes","beginDate":"2015-12-01","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2015-12-01","modifiedBy":"KNABLEJ","dateModified":"2020-12-11","changeNote":"12/11/20 jk Released per 4Q20 qtrly review; used on form, added CITN origin. 12/1/2015 jk created for CITN-10 protocol.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5430052","version":"1","preferredName":"Patient Without Injury Prior And Post Therapeutic Procedure Biopsy Eligibility Determination Indicator","preferredDefinition":"The indication that a patient meets the criteria regarding receiving pre and post treatment biopsies.","longName":"5409954v1.0:3506068v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AC41803-2237-6EF2-E050-BB89AD4351DE","latestVersionIndicator":"Yes","beginDate":"2016-08-23","endDate":null,"createdBy":"KARNATAA","dateCreated":"2016-08-23","modifiedBy":"KARNATAA","dateModified":"2016-08-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5431731","version":"1","preferredName":"Injection Procedure Ultrasound Requirement Indicator","preferredDefinition":"The indication if the patient required an ultrasound for the injection procedure.","longName":"5431706v1.0:3506068v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AEAA16D-F8C2-5BB7-E050-BB89AD434FBE","latestVersionIndicator":"Yes","beginDate":"2016-08-25","endDate":null,"createdBy":"KARNATAA","dateCreated":"2016-08-25","modifiedBy":"FORMBUILDER","dateModified":"2016-12-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5547627","version":"1","preferredName":"Surgical Procedure Postoperative Outcome","preferredDefinition":"The postoperative results of a surgical procedure.","longName":"5543521v1.0:5546613v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FDDD164-A9EC-195E-E053-F662850A10AB","latestVersionIndicator":"Yes","beginDate":"2016-10-27","endDate":null,"createdBy":"KARNATAA1","dateCreated":"2016-10-27","modifiedBy":"FORMBUILDER","dateModified":"2016-12-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5557347","version":"1","preferredName":"Prior Therapeutic Procedure Best Response Type","preferredDefinition":"The best response reported for a prior therapy administered.","longName":"2195482v1.0:5547727v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"402BC3A1-0D1B-4D81-E053-F662850A2E98","latestVersionIndicator":"Yes","beginDate":"2016-10-31","endDate":null,"createdBy":"KARNATAA1","dateCreated":"2016-10-31","modifiedBy":"FORMBUILDER","dateModified":"2016-12-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5557965","version":"1","preferredName":"Prior Therapeutic Procedure Discontinue Reason","preferredDefinition":"The reason for discontinuation of prior therapy.","longName":"5557650v1.0:5557877v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4030534B-1FCD-23B8-E053-F662850A29E1","latestVersionIndicator":"Yes","beginDate":"2016-10-31","endDate":null,"createdBy":"KARNATAA1","dateCreated":"2016-10-31","modifiedBy":"SOKKERL","dateModified":"2019-06-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5917298","version":"1","preferredName":"Kaposi Sarcoma Lesion Appearance Type","preferredDefinition":"A description of the appearance of a oral lesion related to Kaposi Sarcoma.","longName":"KS_ LES_APPEAR_TP","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55DFA9F5-DAE3-4718-E053-F662850AD5D3","latestVersionIndicator":"Yes","beginDate":"2017-08-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-03","modifiedBy":"SOKKERL","dateModified":"2017-08-07","changeNote":"8/3/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5917738","version":"1","preferredName":"Kaposi Sarcoma Lesion Assessment Status Type","preferredDefinition":"Text term that represents Kaposi Sarcoma oral and visceral lesions","longName":"KS_LES_ASSESS_STAT_TP","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55E0B39F-442C-107E-E053-F662850A76A3","latestVersionIndicator":"Yes","beginDate":"2017-08-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-03","modifiedBy":"SOKKERL","dateModified":"2017-08-07","changeNote":"8/3/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5918245","version":"1","preferredName":"Kaposi Sarcoma Malignant Neoplasm Flat Quantity Count","preferredDefinition":"The quantity or number of flat malignant neoplasms (lesions) in Kaposi Sarcoma.","longName":"KP_MAL_FLT_CT","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55F0EAA4-E490-741B-E053-F662850A0CAC","latestVersionIndicator":"Yes","beginDate":"2017-08-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-04","modifiedBy":"SOKKERL","dateModified":"2017-08-14","changeNote":"8/4/2017","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5918250","version":"1","preferredName":"Kaposi Sarcoma Malignant Neoplasm Nodular Quantity Count","preferredDefinition":"The quantity or number of nodular malignant neoplasms (lesions) in Kaposi Sarcoma.","longName":"KP_MAL_NOD_CT","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55F131EB-9534-6BA7-E053-F662850A1F9C","latestVersionIndicator":"Yes","beginDate":"2017-08-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-04","modifiedBy":"SOKKERL","dateModified":"2017-08-14","changeNote":"8/4/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5918253","version":"1","preferredName":"Kaposi Sarcoma Lesion Assessment Text","preferredDefinition":"The free-text field used to describe a visceral lesion.","longName":"KP_LES_ASSESS_TX","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55F0C5DA-FF36-0CF5-E053-F662850A29C8","latestVersionIndicator":"Yes","beginDate":"2017-08-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-04","modifiedBy":"SOKKERL","dateModified":"2017-08-07","changeNote":"8/4/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5918256","version":"1","preferredName":"Kaposi Sarcoma Disease Anatomic Location Type","preferredDefinition":"The assessment of location of Kaposi Sarcoma lesion.","longName":"KP_DX_LOC_TYP","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55F204D8-D386-76B3-E053-F662850AB34C","latestVersionIndicator":"Yes","beginDate":"2017-08-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-04","modifiedBy":"SOKKERL","dateModified":"2017-08-07","changeNote":"8/4/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5918276","version":"1","preferredName":"Kaposi Sarcoma Lesion Total Type","preferredDefinition":"The number associated with the total kaposi sarcoma lesions.","longName":"KP_LES_TTL_TP","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55F26676-9E3D-6C50-E053-F662850ABCBD","latestVersionIndicator":"Yes","beginDate":"2017-08-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-04","modifiedBy":"SOKKERL","dateModified":"2017-08-14","changeNote":"8/4/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5918285","version":"1","preferredName":"Tumor Response Clinical Type","preferredDefinition":"A status of baseline response of cancer to treatment based on medical evaluations of lesions.","longName":"TUM_RES_TP","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55F37DB7-CE22-6ABD-E053-F662850A8CBB","latestVersionIndicator":"Yes","beginDate":"2017-08-04","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-04","modifiedBy":"SOKKERL","dateModified":"2017-08-07","changeNote":"8/4/17 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5918302","version":"1","preferredName":"Kaposi Sarcoma Lesion Critera Assessment","preferredDefinition":"The response assessment of the final result of a determination of the value, significance, or extent of Kaposi Sarcoma lesions.","longName":"KS_LES_ASSES","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"562BAB20-9C9F-3679-E053-F662850A5175","latestVersionIndicator":"Yes","beginDate":"2017-08-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-08-07","modifiedBy":"SOKKERL","dateModified":"2017-08-07","changeNote":"8/7/2017 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5983977","version":"1","preferredName":"Disease or Disorder Skin Reaction Observed Yes No Indicator","preferredDefinition":"The yes/no indicator for information related to the observation of a skin flare reaction response generated by a stimulus.","longName":"5983976v1.0:3506068v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A40EDB2-2280-1784-E053-F662850AF9BD","latestVersionIndicator":"Yes","beginDate":"2017-09-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2017-09-28","modifiedBy":"MAESKEB","dateModified":"2017-09-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6005183","version":"1","preferredName":"Serological Positive HBsAb And Negative HBcAb Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable response that asks if the patient has a serological determined positive HBsAb and a negative HBcAb.","longName":"6005169v1.0:3506034v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BC529DA-9919-1DED-E053-F662850A4DE5","latestVersionIndicator":"Yes","beginDate":"2017-10-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2017-10-17","modifiedBy":"KNABLEJ","dateModified":"2020-12-11","changeNote":"12/11/20 jk Released per 4Q20 qtrly review; used on form.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6005184","version":"1","preferredName":"Chronic HBV Antiretroviral Therapy Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable response that asks if the patient has chronic hepatitis caused by the hepatitis B virus that is suppressed  by appropriate antiretroviral therapy with activity against HBV.","longName":"6005173v1.0:3506034v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BC758FA-EF24-17A1-E053-F662850A064B","latestVersionIndicator":"Yes","beginDate":"2017-10-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2017-10-17","modifiedBy":"KNABLEJ","dateModified":"2020-12-11","changeNote":"12/11/20 jk Released per 4Q20 qtrly review; used on form.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6005185","version":"1","preferredName":"Hepatitis C Virus Positive Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable response that asks if the patient has active hepatitis C that was qualitatively detected.","longName":"6005176v1.0:3506034v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BC41D6F-9D27-4F79-E053-F662850A5447","latestVersionIndicator":"Yes","beginDate":"2017-10-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2017-10-17","modifiedBy":"KNABLEJ","dateModified":"2020-12-11","changeNote":"12/11/20 jk Released per 4Q20 qtrly review; used on form.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6005186","version":"1","preferredName":"Positive HCV Negative Hepatitis C RNA Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable response that asks if the patient has a positive HCV serology with no detectable HCV RNA.","longName":"6005179v1.0:3506034v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BC529DA-9945-1DED-E053-F662850A4DE5","latestVersionIndicator":"Yes","beginDate":"2017-10-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2017-10-17","modifiedBy":"KNABLEJ","dateModified":"2020-12-11","changeNote":"12/11/20 jk Released per 4Q20 qtrly review; used on form.  6/1/20 jk Reviewed as part of 2Q20 Steward review; need new CITN POC input.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6005187","version":"1","preferredName":"Complete Hepatitis C Virus Therapeutic Procedure Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The yes/no/not applicable response that asks if the patient has successfully completed treatment for HCV.","longName":"6005182v1.0:3506034v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BC8130D-20DF-5A9F-E053-F662850AD43C","latestVersionIndicator":"Yes","beginDate":"2017-10-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2017-10-17","modifiedBy":"KNABLEJ","dateModified":"2020-12-11","changeNote":"12/11/20 jk Released per 4Q20 qtrly review; used on form.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6010216","version":"1","preferredName":"Sezary Cell Assessment Performed Yes No Indicator","preferredDefinition":"A yes/no response to indicate if an assessment was performed for the presence of circulatory Sezary cells.","longName":"6010119v1.0:3506068v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C4B34B9-8541-06D9-E053-F662850A1677","latestVersionIndicator":"Yes","beginDate":"2017-10-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2017-10-24","modifiedBy":"KNABLEJ","dateModified":"2020-12-11","changeNote":"12/11/20 jk Released per 4Q20 qtrly review; used on form.  10/24/17 jk created to be paired with CDE 5028016.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6035165","version":"1","preferredName":"Extracutaneous Dissemination of Disease Present Indicator","preferredDefinition":"A yes, no, or unknown response to indicate if disease is present beyond the skin level.","longName":"6035164v1.0:3506034v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F4A2C6B-688F-4319-E053-F662850ABFC1","latestVersionIndicator":"Yes","beginDate":"2017-12-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2017-12-01","modifiedBy":"KNABLEJ","dateModified":"2020-12-11","changeNote":"12/11/20 jk Released per 4Q20 qtrly review; used on form, added CITN origin.  12/1/17 jk created for CITN eligibility question.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6319091","version":"1","preferredName":"Low Dose Total Skin Electron Beam Radiation Therapy Greater Than or Equal To 8 Week Complete Yes No Indicator","preferredDefinition":"The response that indicates whether or not at least eight weeks have passed since a patient completed low dose Total Skin Electron Beam Therapy (TSEBT).","longName":"LD_TSEBT_GTE8_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6D861C05-4C56-14AD-E053-F662850A34B7","latestVersionIndicator":"Yes","beginDate":"2018-05-31","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-05-31","modifiedBy":"HARTLEYG","dateModified":"2018-05-31","changeNote":"Curated to support CITN_ghd_05.31.18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6430015","version":"1","preferredName":"Patient Current Clinical Study Enrollment Indicator","preferredDefinition":"An indication as to whether a person is currently registered with an institution for the purpose of receiving medical care as part of a research activity.","longName":"PT_CUR_TRL_ENROLL_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"75C86FC0-27CC-1002-E053-F662850A93CA","latestVersionIndicator":"Yes","beginDate":"2018-09-13","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-09-13","modifiedBy":"ZHWENDY","dateModified":"2023-03-28","changeNote":"9/14/18 jk Per Vivy, release CDE. 9/13/18 jk created for CITN-09 study.","administrativeNotes":"3/28/2023: Added AQT per CADSR0002213.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6430112","version":"1","preferredName":"Stop Initial Treatment Investigator Evaluation of Response Confirmation Indicator","preferredDefinition":"An indication as to whether initial treatment was ended based on investigator confirmation of treatment response.","longName":"SP_INT_TRMT_RESP_CONF_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"75D37B8E-9C3C-17AD-E053-F662850A9A6B","latestVersionIndicator":"Yes","beginDate":"2018-09-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-09-14","modifiedBy":"KNABLEJ","dateModified":"2018-09-14","changeNote":"9/14/18 jk Per Vivy, release CDE.  9/14/18 jk created for CITN-09 study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6430113","version":"1","preferredName":"Stop Initial Treatment Investigator Radiographic Examination Disease Progression Confirmation Indicator","preferredDefinition":"An indication as to whether initial treatment was ended based on investigator confirmation of radiographic disease progression.","longName":"SP_INT_TRMT_RAD_D_P_CONF_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"75D34915-4C6C-4FAC-E053-F662850AF20F","latestVersionIndicator":"Yes","beginDate":"2018-09-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-09-14","modifiedBy":"KNABLEJ","dateModified":"2018-09-14","changeNote":"9/14/18 jk Per Vivy, release CDE.  9/14/18 jk created for CITN-09 study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6430114","version":"1","preferredName":"Any Cancer Treatment Since Last Clinical Trial Agent Dose Indicator","preferredDefinition":"An indication as to whether a person has received any treatment since the last dose of the clinical trial agent.","longName":"PT_TRMT_LAST_AGT_DOSE_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"75D3A499-8240-108D-E053-F662850AA490","latestVersionIndicator":"Yes","beginDate":"2018-09-14","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-09-14","modifiedBy":"KNABLEJ","dateModified":"2018-09-14","changeNote":"9/14/18 jk Per Vivy, release CDE.  9/14/18 jk created for CITN-09 study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6548370","version":"1","preferredName":"Expedited Reporting Required Indicator","preferredDefinition":"A yes/no response to indicate whether expedited reporting of an event is required.","longName":"EXP_RPT_REQ_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"79F46B82-429E-59D9-E053-F662850AB497","latestVersionIndicator":"Yes","beginDate":"2018-11-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-11-05","modifiedBy":"KNABLEJ","dateModified":"2018-11-07","changeNote":"11/7/18 jk reviewed by Vivy; ok to release. 11/5/18 jk created for CITN study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6551895","version":"1","preferredName":"Protocol Deviation Discovery Date","preferredDefinition":"The date on which a variation from processes or procedures defined in a protocol was first discovered.","longName":"PROT_DEV_DISCV","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7A17E8B4-B6CB-02B0-E053-F662850AD8B3","latestVersionIndicator":"Yes","beginDate":"2018-11-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-11-07","modifiedBy":"MAESKEB","dateModified":"2020-08-12","changeNote":"11/15/18 jk released per Vivy. 11/7/18 jk Created for date of discovery of protocol deviation; use CDE 2435009 for notification of the PD.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6551907","version":"1","preferredName":"Protocol Deviation Occurrence Code","preferredDefinition":"Information related to the occurrence of a protocol deviation._A variation from processes or procedures defined in a protocol. Deviations usually do not preclude the overall evaluability of subject data for either efficacy or safety, and are often acknowledged and accepted in advance by the sponsor. (CDISC Glossary)_A symbol or combination of symbols which is assigned to the members of a collection.","longName":"PROTO_DEV_CD","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7A17661E-E87A-552A-E053-F662850A6F6F","latestVersionIndicator":"Yes","beginDate":"2018-11-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-11-07","modifiedBy":"KNABLEJ","dateModified":"2018-11-15","changeNote":"11/15/18 jk released per Vivy.  11/7/18 jk created for CITN specific PD code set.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6551923","version":"1","preferredName":"Protocol Deviation Occurrence Participant Action Reason","preferredDefinition":"Information related to a protocol deviation as to why a participant may not continue on the study.","longName":"2434996v1.0:6551920v1.0","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":"CITN CRF: Cancer Immunotherapy Trials Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7A1A7B69-0D6A-742A-E053-F662850A5EC6","latestVersionIndicator":"Yes","beginDate":"2018-11-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-11-07","modifiedBy":"KNABLEJ","dateModified":"2018-11-15","changeNote":"11/15/18 jk released per Vivy.  11/7/18 jk created for CITN specific question and response set.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6563012","version":"1","preferredName":"Patient Sarcoma Reviewed Metastatic Or Unresectable Disease or Disorder Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"Indicator of whether the patient meets the eligibility requirements for participation in a clinical trial with regards to having sarcoma that has been reviewed and is metatstatic or unresectable.","longName":"SARC_RVW_CTEC_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B100B49-AE6E-33A5-E053-F662850A7904","latestVersionIndicator":"Yes","beginDate":"2018-11-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-11-19","modifiedBy":"HARTLEYG","dateModified":"2018-11-20","changeNote":"Curated for CITN_11.19.18_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6563013","version":"1","preferredName":"Patient Prior First-Line Chemotherapy Administration Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Indicator of whether the patient meets the eligibility requirements for participation in a clinical trial with regards to having at least one prior line of chemotherapy.","longName":"PR_FIRLIN_CHEMO_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B0ABFB3-275D-1383-E053-F662850A0FBF","latestVersionIndicator":"Yes","beginDate":"2018-11-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-11-19","modifiedBy":"ZHWENDY","dateModified":"2024-01-18","changeNote":"Curated for CITN_11.19.18_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6563014","version":"1","preferredName":"Patient Resectable Neoplasm Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"Indicator of whether the patient meets the eligibility requirements for participation in a clinical trial with regarding having a resectable neoplasm.","longName":"RES_NEOPLASM_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B0FE162-CF50-2B58-E053-F662850A7C7B","latestVersionIndicator":"Yes","beginDate":"2018-11-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-11-19","modifiedBy":"HARTLEYG","dateModified":"2018-11-20","changeNote":"Curated for CITN_11.19.18_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6563015","version":"1","preferredName":"Patient Sufficient Hematologic And Target Organ Function Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Indicator of whether the patient meets the eligibility requirements for participation in a clinical trial with regarding having adequate hematologic and end organ function.","longName":"HEM_ENDORG_FCTN_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B0AE04D-8D85-2FFB-E053-F662850AEE16","latestVersionIndicator":"Yes","beginDate":"2018-11-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-11-19","modifiedBy":"HARTLEYG","dateModified":"2018-11-20","changeNote":"Curated for CITN_11.19.18_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6563016","version":"1","preferredName":"Patient Active Therapeutic Procedure Malignant Neoplasm Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Indicator that the patient meets the eligibility requirements for participation in a clinical trial with regards to receiving active therapy for a malignant neoplasm.","longName":"ACT_TX_MALIG_NEO_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B0ABAB6-2D3F-14AA-E053-F662850AC72C","latestVersionIndicator":"Yes","beginDate":"2018-11-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-11-19","modifiedBy":"HARTLEYG","dateModified":"2021-11-30","changeNote":"Curated for CITN_11.19.18_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6563017","version":"1","preferredName":"Person Human Immunodeficiency Virus Highly Active Antiretroviral Therapy Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Indicator that the patient meets the eligibility requirements for participation in a clinical trial with regards to being HIV positive and receiving antiretroviral therapy.","longName":"HIV_ACT_RETROVIR_IND","contextName":"CITN","contextVersion":"1","dataElementConceptPublicId":"4155935","dataElementConceptVersion":"1","valueDomainPublicId":"4156012","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B0ABFB3-277E-1383-E053-F662850A0FBF","latestVersionIndicator":"Yes","beginDate":"2018-11-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-11-19","modifiedBy":"HARTLEYG","dateModified":"2018-11-20","changeNote":"Curated for CITN_11.19.18_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}]}